IP Library Granted Patent US 11,090,320
Granted Patent B2
US 11,090,320 · App. 17/176,276 · Granted Aug 17, 2021

Compositions for reducing mitochondrial dysfunction

Inventor: Louis Dischler (Spartanburg, SC)
A61K31/7004A61K31/194A61K31/20A61K31/26A61K31/353A61K31/455A61K31/4745A61K31/5415A61K31/706A61P39/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,090,320
App. No.
17/176,276
Granted
Aug 17, 2021
Kind
B2
Abstract

Disclosed are methods and compositions for reducing the epigenetic age of organisms, especially that of adult humans, which provide for proliferating endogenous stem cells, removing aberrant epigenetic marks from chromosomes and mitochondrial DNA, and replacement of senescent cells.

Claims (16)

1. A composition for reducing a subject's methylated mitochondrial DNA, comprising:

a mitochondrial fission promoter consisting of a dose of about 100 mg to about 5 g nicotinamide and/or nicotinic acid, and optionally about 100 mg to about 20 g ribose; and

a mitochondrial biogenesis promoter consisting of a dose of about 1 mg to about 100 mg of pyrroloquinoline quinone (PQQ) and/or PQQ derivatives.

2. The composition as recited in claim 1 , further comprising:

a demethylase promoter consisting of a dose of about 50 mg to about 50 g of alpha-ketoglutarate or analog thereof.

3. The composition as recited in claim 1 , further comprising about 100 mg to about 20 g ribose.

4. The composition as recited in claim 2 , further comprising about 100 mg to about 20 g ribose.

5. The composition as recited in claim 2 , wherein the alpha-ketoglutarate or analog thereof is selected from the group consisting of: alpha-ketoglutarate, ammonium alpha-ketoglutarate, arginine alpha-ketoglutarate, calcium alpha-ketoglutarate, creatine alpha-ketoglutarate, glutamine alpha-ketoglutarate, leucine alpha-ketoglutarate, lithium alpha-ketoglutarate, magnesium alpha-ketoglutarate, ornithine alpha-ketoglutarate, potassium alpha-ketoglutarate, sodium alpha-ketoglutarate, and taurine alpha-ketoglutarate.

6. The composition as recited in claim 1 , wherein the composition is formulated into a dose deliverable as powder, liquid, paste, capsules, caplets or tablets.

7. A composition for reducing a subject's methylated mitochondrial DNA, comprising:

a mitochondrial fission promoter consisting of a dose of about 80 mg to about 8 g apigenin; and

a mitochondrial biogenesis promoter consisting of a dose of about 1 mg to about 100 mg of pyrroloquinoline quinone (PQQ) and/or PQQ derivatives.

8. The composition as recited in claim 7 , further comprising:

a demethylase promoter consisting of a dose of about 50 mg to about 50 g of alpha-ketoglutarate.

9. The composition as recited in claim 8 , wherein the alpha-ketoglutarate or analog thereof is selected from the group consisting of: alpha-ketoglutarate, ammonium alpha-ketoglutarate, arginine alpha-ketoglutarate, calcium alpha-ketoglutarate, creatine alpha-ketoglutarate, glutamine alpha-ketoglutarate, leucine alpha-ketoglutarate, lithium alpha-ketoglutarate, magnesium alpha-ketoglutarate, ornithine alpha-ketoglutarate, potassium alpha-ketoglutarate, sodium alpha-ketoglutarate, and taurine alpha-ketoglutarate.

10. The composition as recited in claim 7 , wherein the composition is formulated into a dose deliverable as powder, liquid, paste, capsules, caplets or tablets.

Continuity (5)
Continuation In Part 16540200 · Aug 14, 2019
Provisional Application 62980501 · Feb 24, 2020
Provisional Application 63136662 · Jan 13, 2021
Provisional Application 62719637 · Aug 18, 2018
Related Publication 20210161925A1 · Jun 3, 2021